Neostigmine and its salts (e.g. neostigmine bromide (INN))
Neostigmine and its salts (e.g. neostigmine bromide (INN)) is listed in Annex II as a prohibited substance for cosmetic products placed on the EU market.
Chemical identity and properties

Neostigmine Bromide
Neostigmine bromide is the bromide salt of neostigmine. It contains a neostigmine. — ChEBI
- IUPAC name
- [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium bromide
- Molecular formula
- C12H19BrN2O2
- Molecular weight
- 303.20 g/mol
- Exact mass
- 302.06299 Da
- Topological polar surface area
- 29.5 Ų
- Hydrogen-bond donors
- 0
- Hydrogen-bond acceptors
- 3
- Covalent units
- 2
- Defined stereocentres
- 0
Also known as
16 more reported names
External database identifiers
- ChEBI:CHEBI:179557
- ChEMBL:CHEMBL54126
- EPA DTXSID:DTXSID9041075
- PubMed:1853
Evidence from additional scientific databases
NIH PubChem PUG-View
Attributed physical-property, hazard, environmental and use annotations.
- Solubility: >45.5 [ug/mL] (The mean of the results at pH 7.4) Source: Sanford-Burnham Center for Chemical Genomics
- Signal: Danger Source: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H300 (95.1%): Fatal if swallowed [Danger Acute toxicity, oral]; H310 (95.1%): Fatal in contact with skin [Danger Acute toxicity, dermal]; H315 (97.6%): Causes skin irritation [Warning Skin corrosion/irritation]; H317 (95.1%): May cause an allergic skin reaction [Warning Sensitization, Skin]; H319 (97.6%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H330 (95.1%): Fatal if inhaled [Danger Acute toxicity, inhalation]; H334 (95.1%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory]; H335 (95.1%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation] Source: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P233, P260, P261, P262, P264, P264+P265, P270, P271, P272, P280, P284, P301+P316, P302+P352, P304+P340, P305+P351+P338, P316, P319, P320, P321, P330, P332+P317, P333+P317, P337+P317, P342+P316, P361+P364, P362+P364, P403, P403+P233, P405, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 41 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record
Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.
Additional source coverage and match status
| Source | Result | Checked |
|---|---|---|
| NIH PubChem PUG-View | Exact match | 2026-08-31 |
A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.
Retrieved from NIH PubChem on 2026-09-02 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.
Record details
Chemical name
Neostigmine and its salts (e.g. neostigmine bromide (INN))
Regulatory information
Key data
Related records for Neostigmine and its salts (e.g. neostigmine bromide (INN))
Direct matches are limited for this record, so nearby entries from Annex II are shown as well.
Naphazoline (INN) and its salts
1- and 2-Naphthylamines and their salts
Inorganic nitrites, with exception of sodium nitrite
Nitrocresols and their alkali metal salts
What Annex II means for Neostigmine and its salts (e.g. neostigmine bromide (INN))
Neostigmine and its salts (e.g. neostigmine bromide (INN)) is listed as a prohibited substance under Annex II of EU Cosmetics Regulation 1223/2009 and must not be intentionally added. Article 17 separately addresses unintended small quantities that are technically unavoidable under good manufacturing practice and compatible with the Article 3 safety requirement.
Formulators must screen their ingredients and raw materials to ensure none contain this substance. Suppliers should provide documentation confirming absence when requested.
The page also surfaces 12 related annex records with overlapping identifiers, annex logic or naming patterns.
Compliance checklist
- Verify this substance is absent from all raw materials and finished formulations.
- Request absence confirmation or CoA from raw material suppliers.
- Document the screening result in the Product Information File (PIF).
Frequently asked questions
Source note for Annex II record Neostigmine and its salts (e.g. neostigmine bromide (INN))
This page summarizes one Annex II record for Neostigmine and its salts (e.g. neostigmine bromide (INN)) from public European Commission cosmetic materials and adds linked inventory or identifier matches when available.
Use this record page to review Annex II conditions for Neostigmine and its salts (e.g. neostigmine bromide (INN)), but confirm any final regulatory decision against the current official annex wording and source files.
Tools & next steps
Check your formula
Paste a full INCI list to detect Neostigmine and its salts (e.g. neostigmine bromide (INN)) and other flagged EU annex records in one pass.
INCI CheckerCompare entries
Compare Neostigmine and its salts (e.g. neostigmine bromide (INN)) side by side with another annex record to review differences in restrictions, concentrations and annex placement.
CompareBrowse the annex
See all records in Annex II and compare regulatory conditions across substances in this annex.
Open Annex II